Cellworks

Cancer is a heterogeneous disease, yet treatment guidelines focus on one mutation at a time and do not consider mutational interactions and mechanisms of action that often cause drug resistance. The number of FDA approved cancer drugs has skyrocketed in the past decade, complicating the selection of the best treatment for individual patients. Cellworks provides a decision support system for oncologists challenged with determining the best treatment for treatment-naive as well as relapsed or refractory patients. Cellworks provides two products to assist in treating patients diagnosed with specific oncology indications. Cellworks SingulaTM reports provide personalized response predictions to Standard Care therapies for front-line patients.